Fej-nyaki daganatok: ki dolgozik rajta

Intézményenként egy kártya. Szűrhetsz célpontra, országra, vagy csak az EU-13 (Horizon Europe felzárkózó) országok intézményeire.

• Minden célpont
• PD-1 69
• PD-L1 42
• TP53 7
• EGFR 33
• PI3K 6
• STAT3 1
• BRAF 0
• AKT 2
• mTOR 0
• HER2 6
• RET 0
• MAPK 0
• ERK 0
• STING 0
• PTEN 1
• TERT 0
• CTNNB1 0
• JAK 1
• CTLA-4 4
• NRF2 0
• VEGF 4
• MYC 0
• YAP 1
• HIF-1 0
• MET 3
• AMPK 0
• CLDN18 0
• IL-6 2
• JNK 0
• PARP 1
• FGFR 1
• B7-H3 5
• COX-2 0
• GPX4 0
• LAG-3 2
• TROP2 5
• EZH2 0
• MEK 0
• CD47 1
• METTL3 0
• PIK3CA 4
• CDK4/6 2
• NLRP3 0
• ATM 0
• PKM2 0
• TNF 0
• FAK 0
• MMP-9 0
• PPAR 0
• PSMA 1
• TLR4 0
• BCL-2 0
• HSP90 0
• KRAS 0
• NOTCH1 0
• NTRK 1
• ALK 0
• CD40 1
• CXCR4 0
• HER3 4

Az EU-13 szűrő, nem rangsor: csak szűkíti a listát.

1127 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer

  NCT04001543· Institut du Cancer de Montpellier - Val d'Aurelle· Frissítve: 2026. nov. 9.

  “A change in patient care. Competing trials with the expansion of immunotherapies, Difficulties in manufacturing and obtaining products for double-blind studies. The health situation, with an temporary halt due to COVID-19.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

  NCT01810913· National Cancer Institute (NCI)· Frissítve: 2026. nov. 2.

  “Other - Assessing accrual feasibility”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Frissítve: 2026. okt. 26.

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of E7130 in Participants With Solid Tumors

  NCT03444701· Eisai Co., Ltd.· Frissítve: 2026. okt. 23.

  “The trial was prematurely terminated due to the sponsor's decision.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Digital Phenotyping of Psychological Distress in Skin Cancer Patients

  NCT07670403· West China Hospital· Frissítve: 2026. okt. 16.

  “poor accrual”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

  NCT06741982· West China Hospital· Frissítve: 2026. okt. 16.

  “The study was withdrawn prior to participant enrollment due to administrative and protocol optimization considerations.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

  NCT06091930· Boehringer Ingelheim· Frissítve: 2026. okt. 14.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

  NCT03881488· Compass Therapeutics· Frissítve: 2026. okt. 9.

  “The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

  NCT07513324· Dana-Farber Cancer Institute· Frissítve: 2026. okt. 8.

  “study halted prematurely prior to enrollment of first participant”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Mental Health App for Cancer Survivors Study

  NCT06472726· University of Wisconsin, Madison· Frissítve: 2026. okt. 2.

  “App developer is no longer in business”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

  NCT07667400· National Cancer Institute (NCI)· Forrás

• Unplanned Hospitalization and Emergency Department Use in Patients With Head and Neck Cancer Receiving Radiotherapy

  NCT07929194· Xiangya Hospital of Central South University· Forrás

• Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  NCT06589804· National Cancer Institute (NCI)· Forrás

• A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy

  NCT05207098· Memorial Sloan Kettering Cancer Center· Forrás

• Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot Study

  NCT07919444· Shaukat Khanum Memorial Cancer Hospital & Research Centre· Forrás

• Phenotype-based Model for Managing Chronic Post-treatment Pain Among Head and Neck Cancer Survivors: a Pilot Study

  NCT07919457· Shaukat Khanum Memorial Cancer Hospital & Research Centre· Forrás

• Feasibility of Cough Skill Training in Individuals With Head and Neck Cancer

  NCT07756684· Boston University Charles River Campus· Forrás

• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

  NCT05063552· National Cancer Institute (NCI)· Forrás

• A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

  NCT06385080· Janssen Research & Development, LLC· Forrás

• A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

  NCT07219212· Johnson & Johnson Enterprise Innovation Inc.· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 84
• Organoids 23
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 13
• Gene Expression Profiling 243
• Sequence Analysis, RNA 26
• Whole Genome Sequencing 6
• Exome Sequencing 22
• Proteomics 64
• Metabolomics 43
• Mass Spectrometry 14
• Flow Cytometry 56
• Immunohistochemistry 330
• Liquid Biopsy 33
• Circulating Tumor DNA 56
• Xenograft Model Antitumor Assays 305
• Positron-Emission Tomography 83
• Magnetic Resonance Imaging 273
• Machine Learning 232
• Deep Learning 186
• Cohort Studies 295
• Genome-Wide Association Study 55

• Health-related quality of life as a complementary prognostic marker in nasopharyngeal carcinoma: an explainable machine-learning survival analysis.

  Qual Life Res, 2026. nov.

• AI-driven infrared spectroscopy in salivary oral leukoplakia.

  Clin Oral Investig, 2026. nov.

• Explainable computational framework for subtype classification and biomarker identification in head and neck squamous cell carcinoma using machine learning.

  PLoS One, 2026. nov.

• Early vs late fusion of qMIDS with machine learning based classifiers for oral cancer diagnosis from gene expression data.

  PLoS Comput Biol, 2026. okt.

• Incorporating natural language processing-derived features from pathology reports into machine learning models to predict differentiated thyroid cancer recurrence.

  Front Endocrinol (Lausanne), 2026. okt.

• Network pharmacology and machine learning reveal kit as a target of roburic acid in anaplastic thyroid carcinoma: Preliminary in vitro validation.

  PLoS One, 2026. okt.

• Detection of Cervical Nodal Metastasis in Oral Squamous Cell Carcinoma Using Elastic Scattering Spectroscopy: Ex Vivo Diagnostic Modeling Study.

  JMIR Cancer, 2026. okt.

• Effectiveness of radiotherapy or chemoradiotherapy in older patients with advanced-stage, non-surgically treated head and neck cancer: A machine learning analysis.

  Med Oncol, 2026. okt.

• A genetic algorithm-optimized EWMA control chart integrating machine learning-based risk prediction for multistage thyroid cancer treatment monitoring.

  PLoS One, 2026. okt.

• An explainable and leakage-aware machine learning model for early risk stratification of radioiodine-refractory differentiated thyroid cancer: development and single-center geographic external validation.

  Front Endocrinol (Lausanne), 2026. okt.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.